Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00200369 |
Recruitment Status
:
Completed
First Posted
: September 20, 2005
Last Update Posted
: November 5, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
HIV Infection | Device: MEMS cap |
The existing dogma is that patients receiving highly active antiretroviral therapy (HAART) to treat their HIV infection must take at least 95% of prescribed doses in order to maintain full suppression of viral replication. This belief is largely based on a single study that was performed between 1997 and 1999 (Ann Int Med 2000;133:21-30). The vast majority of patients in this study were receiving regimens based on either indinavir, nelfinavir, ritonavir, or saquinavir. All of these agents have relatively short half-lives, and therefore must be taken on time two or three times per day. Newer medications such as lopinavir/ritonavir (Kaletra) feature much more favorable pharmacokinetic profiles. On the basis of improved pharmacokinetics, there is reason to believe that regimens built around such agents may be more forgiving of missed medication doses.
This study aims to enroll 90 patients from the MMC I.D. Clinic who are either receiving or are about to receive Kaletra. Patients who agree to participate will be furnished with a MEMS cap, a bottle cap that electronically records each time that the bottle is opened and stores the data for computer download, and will undergo electronic monitoring of their Kaletra adherence for a period of siz months. Adherence data will not be reviewed during the study, but at study end (and at interim time points), the investigators will analyze the MEMS cap data from patients who have completed the study in order to determine the threshold value of adherence necessary to achieve satisfactory rates (i.e. 70-80%) of complete virologic suppression.
An additional aim of the study is to collect specimens from patients receiving Kaletra based regimens who experience virologic failure and to archive them for possible studies of genotypic and phenotypic resistance in the future.
Study Type : | Observational |
Estimated Enrollment : | 90 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen |
Study Start Date : | May 2004 |
Actual Study Completion Date : | March 2006 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- HIV infection
- Receiving twice daily Kaletra at an FDA approved dosage
- Age>18 years
- CD4 and viral load available within seven day of enrollment
- Patient willingness to accept MEMS cap monitoring
- HIV genotype within 60 days of enrollment for patients with viral load>1000
- Patient willingness to grant informed consent and complete five study visits
Exclusion Criteria:
- Provider or patient deem it unlikely that Kaletra therapy will continue for the ensuing 24 weeks
- Prescription of any medication that is contraindicated for Kaletra recipients

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00200369
United States, New York | |
Montefiore Medical Center I.D. Clinic | |
Bronx, New York, United States, 10467 |
Principal Investigator: | Jonathan Shuter, MD | Montefiore Medical Center |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00200369 History of Changes |
Other Study ID Numbers: |
03-10-268 Abbott Laboratories #378-03-71 |
First Posted: | September 20, 2005 Key Record Dates |
Last Update Posted: | November 5, 2009 |
Last Verified: | November 2009 |
Keywords provided by Montefiore Medical Center:
HIV Adherence Antiretroviral therapy Protease inhibitor Lopinavir |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |